Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.
Ablation
Focal therapy
Hormone-sensitive
Oligometastatic
Prostate cancer
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
24
03
2022
accepted:
08
07
2022
medline:
11
8
2023
pubmed:
3
10
2022
entrez:
2
10
2022
Statut:
ppublish
Résumé
Focal therapy (FT) is gaining increasing acceptance in the management of localized prostate cancer particularly due to its favorable safety. Preliminary evidence suggests advantageous utilization of local treatment in the field of oligometastatic prostate cancer (OMPC). Since data on the utilization of FT in OMPC are scarce, we sought to summarize available evidence. For this narrative comprehensive review, we employed PubMed Growing evidence points to distinct differences in the biologic behavior and molecular signaling processes of OMPC as compared to polymetastatic disease (PMPC). No established biomarkers are available to accurately identify OMPC yet, while several candidates are currently under investigation. The evolution of molecular imaging is set to aid in selecting patients benefitting most from local management. Differences between OMPC and PMPC should be considered when designing the optimal therapeutic strategy. While efficacy data for FT in comparison to standard care in OMPC are scarce, longer progression-free survival and time to castration resistance have been demonstrated for bone metastatic prostate cancer with the primary tumor treated by cryosurgery followed by androgen deprivation therapy (ADT) compared to ADT alone. Ongoing research efforts are eagerly awaited to better characterize OMPC and establish customized strategies for patients with this condition.
Identifiants
pubmed: 36183289
doi: 10.1007/s00345-022-04162-5
pii: 10.1007/s00345-022-04162-5
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2077-2090Investigateurs
Igor Tsaur
(I)
Roman A Blaheta
(RA)
Maximilian Brandt
(M)
Robert Dotzauer
(R)
Jonathan Olivier
(J)
Giorgio Gandaglia
(G)
Christian Surcel
(C)
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ong S, O’Brien J, Medhurst E, Lawrentschuk N, Murphy D, Azad A (2021) Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review. Transl Androl Urol. 10(10):3918–3930. https://doi.org/10.21037/tau-20-1118
doi: 10.21037/tau-20-1118
pubmed: 34804835
pmcid: 8575582
Teo MY, Rathkopf DE, Kantoff P (2019) Treatment of advanced prostate cancer. Annu Rev Med 70:479–499. https://doi.org/10.1146/annurev-med-051517-011947
doi: 10.1146/annurev-med-051517-011947
pubmed: 30691365
pmcid: 6441973
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa2119115
doi: 10.1056/NEJMoa2119115
pubmed: 36516098
pmcid: 10309537
Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75(3):410–418. https://doi.org/10.1016/j.eururo.2018.09.008
doi: 10.1016/j.eururo.2018.09.008
pubmed: 30266309
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3
doi: 10.1016/S0140-6736(18)32486-3
pubmed: 30355464
pmcid: 6269599
Ali A, Hoyle A, Haran AM, Brawley CD, Cook A, Amos C et al (2021) Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 7(4):555–563. https://doi.org/10.1001/jamaoncol.2020.7857
doi: 10.1001/jamaoncol.2020.7857
pubmed: 33599706
pmcid: 7893550
Knipper S, Beyer B, Mandel P, Tennstedt P, Tilki D, Steuber T et al (2020) Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. World J Urol 38(6):1459–1464. https://doi.org/10.1007/s00345-019-02950-0
doi: 10.1007/s00345-019-02950-0
pubmed: 31511970
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650–659. https://doi.org/10.1001/jamaoncol.2020.0147
doi: 10.1001/jamaoncol.2020.0147
pubmed: 32215577
pmcid: 7225913
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, Bruycker AD et al (2020) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial. J Clin Oncol 38(6_suppl):10. https://doi.org/10.1200/JCO.2020.38.6_suppl.1.0
doi: 10.1200/JCO.2020.38.6_suppl.1.0
van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM et al (2018) Focal therapy in primary localised prostate cancer: the European association of urology position in 2018. Eur Urol 74(1):84–91. https://doi.org/10.1016/j.eururo.2018.01.001
doi: 10.1016/j.eururo.2018.01.001
pubmed: 29373215
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8
doi: 10.1200/JCO.1995.13.1.8
pubmed: 7799047
Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8(6):378–382. https://doi.org/10.1038/nrclinonc.2011.44
doi: 10.1038/nrclinonc.2011.44
pubmed: 21423255
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357. https://doi.org/10.1038/nature14347
doi: 10.1038/nature14347
pubmed: 25830880
pmcid: 4413032
Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T et al (2022) Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: analysis of the REMARCC registry. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2022.03.013
doi: 10.1016/j.clgc.2022.03.013
pubmed: 36588000
Antonelli A, Cozzoli A, Simeone C, Zani D, Zanotelli T, Portesi E et al (2006) Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients. BJU Int 97(3):505–508. https://doi.org/10.1111/j.1464-410X.2006.05934.x
doi: 10.1111/j.1464-410X.2006.05934.x
pubmed: 16469016
Raoux L, Maulat C, Mokrane FZ, Fares N, Suc B, Muscari F (2020) Impact of the strategy for curative treatment of synchronous colorectal cancer liver metastases. J Visc Surg 157(4):289–299. https://doi.org/10.1016/j.jviscsurg.2019.10.007
doi: 10.1016/j.jviscsurg.2019.10.007
pubmed: 32089468
Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241(5):715–722. https://doi.org/10.1097/01.sla.0000160703.75808.7d (discussion 22–4)
doi: 10.1097/01.sla.0000160703.75808.7d
pubmed: 15849507
pmcid: 1357126
Debbi K, Loganadane G, To NH, Kinj R, Husain ZA, Chapet S et al (2022) Curative intent Stereotactic Ablative Radiation Therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study. Br J Radiol. https://doi.org/10.1259/bjr.20210033
doi: 10.1259/bjr.20210033
pubmed: 35143326
Lemoine P, Bruand M, Kammerer E, Bogart E, Comte P, Royer P et al (2021) Stereotactic body radiation therapy for oligometastatic breast cancer: a retrospective multicenter study. Front Oncol 11:736690. https://doi.org/10.3389/fonc.2021.736690
doi: 10.3389/fonc.2021.736690
pubmed: 34778049
pmcid: 8581293
Surcel C, Kretschmer A, Mirvald C, Sinescu I, Heidegger I, Tsaur I (2022) Molecular mechanisms related with oligometastatic prostate cancer-is it just a matter of numbers? Cancers (Basel). https://doi.org/10.3390/cancers14030766
doi: 10.3390/cancers14030766
pubmed: 35159033
pmcid: 8872623
Ahmad AE, Leao R, Hamilton RJ (2017) Radical prostatectomy for patients with oligometastatic prostate cancer. Oncology (Williston Park) 31(11):794–802
pubmed: 29179248
Joice GA, Rowe SP, Pienta KJ, Gorin MA (2017) Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. Curr Opin Urol 27(6):533–541. https://doi.org/10.1097/MOU.0000000000000449
doi: 10.1097/MOU.0000000000000449
pubmed: 28863016
Muller PJ, Dietlein M, Kobe C, Heidenreich A, Drzezga A (2022) Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy—experience at a tertiary referral center. Nuklearmedizin. https://doi.org/10.1055/a-1697-8111
doi: 10.1055/a-1697-8111
pubmed: 35388442
Kucharczyk MJ, Gravis G, Niazi T (2019) The biology of oligometastatic prostate cancer: a different beast than polymetastatic prostate cancer. Eur Urol Focus 5(2):117–118. https://doi.org/10.1016/j.euf.2018.11.011
doi: 10.1016/j.euf.2018.11.011
pubmed: 30527643
Buelens S, Poelaert F, Dhondt B, Fonteyne V, De Visschere P, Ost P et al (2018) Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial. Urol Oncol 36(4):158 e13-158 e20. https://doi.org/10.1016/j.urolonc.2017.12.009
doi: 10.1016/j.urolonc.2017.12.009
pubmed: 29336978
Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA et al (2018) Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 73(6):847–855. https://doi.org/10.1016/j.eururo.2018.02.001
doi: 10.1016/j.eururo.2018.02.001
pubmed: 29475737
pmcid: 6010352
Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ et al (2014) MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 33(44):5173–5182. https://doi.org/10.1038/onc.2013.451
doi: 10.1038/onc.2013.451
pubmed: 24166498
Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q et al (2011) MicroRNA expression characterizes oligometastasis(es). PLoS ONE 6(12):e28650. https://doi.org/10.1371/journal.pone.0028650
doi: 10.1371/journal.pone.0028650
pubmed: 22174856
pmcid: 3236765
Janiszewska M, Tabassum DP, Castano Z, Cristea S, Yamamoto KN, Kingston NL et al (2019) Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol 21(7):879–888. https://doi.org/10.1038/s41556-019-0346-x
doi: 10.1038/s41556-019-0346-x
pubmed: 31263265
pmcid: 6609451
Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL et al (2021) The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur Urol 80(5):632–640. https://doi.org/10.1016/j.eururo.2020.12.040
doi: 10.1016/j.eururo.2020.12.040
pubmed: 33419682
pmcid: 10262980
Manini C, Gonzalez A, Buchser D, Garcia-Olaverri J, Urresola A, Ezquerro A et al (2020) Oligometastatic prostate adenocarcinoma. Clinical-pathologic study of a histologically under-recognized prostate cancer. J Pers Med. https://doi.org/10.3390/jpm10040265
doi: 10.3390/jpm10040265
pubmed: 33291528
pmcid: 7761807
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J et al (2019) Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J Urol 37(12):2557–2564. https://doi.org/10.1007/s00345-018-2609-8
doi: 10.1007/s00345-018-2609-8
pubmed: 30578441
Nakamura M, Kageyama SI, Seki M, Suzuki A, Okumura M, Hojo H et al (2021) Liquid biopsy cell-free DNA biomarkers in patients with oligometastatic colorectal cancer treated by ablative radiotherapy. Anticancer Res 41(2):829–834. https://doi.org/10.21873/anticanres.14835
doi: 10.21873/anticanres.14835
pubmed: 33517288
Mimoto R, Kobayashi T, Imawari Y, Kamio M, Kato K, Nogi H et al (2014) Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy. Breast Cancer Res Treat 147(2):317–324. https://doi.org/10.1007/s10549-014-3111-7
doi: 10.1007/s10549-014-3111-7
pubmed: 25156580
Lin J, Chen Z, Li Z, Nong D, Li X, Huang G et al (2021) Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer. Oncol Rep. https://doi.org/10.3892/or.2021.8147
doi: 10.3892/or.2021.8147
pubmed: 34498714
pmcid: 8444191
Yamanaka M, Hayashi M, Yamada S, Sonohara F, Takami H, Inokawa Y et al (2021) A possible definition of oligometastasis in pancreatic cancer and associated survival outcomes. Anticancer Res 41(8):3933–3940. https://doi.org/10.21873/anticanres.15189
doi: 10.21873/anticanres.15189
pubmed: 34281856
Zhao X, Zhang Y, Gao Z, Han Y (2022) Prognostic value of peripheral naive CD8(+) T cells in oligometastatic non-small-cell lung cancer. Future Oncol 18(1):55–65. https://doi.org/10.2217/fon-2021-0728
doi: 10.2217/fon-2021-0728
pubmed: 34608815
Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC et al (2019) Prospective immunophenotyping of CD8(+) T cells and associated clinical outcomes of patients with oligometastatic prostate cancer treated with metastasis-directed SBRT. Int J Radiat Oncol Biol Phys 103(1):229–240. https://doi.org/10.1016/j.ijrobp.2018.09.001
doi: 10.1016/j.ijrobp.2018.09.001
pubmed: 30205124
Guo Y, Arciero CA, Jiang R, Behera M, Peng L, Li X (2020) Different breast cancer subtypes show different metastatic patterns: a study from a large public database. Asian Pac J Cancer Prev 21(12):3587–3593. https://doi.org/10.31557/APJCP.2020.21.12.3587
doi: 10.31557/APJCP.2020.21.12.3587
pubmed: 33369456
pmcid: 8046324
Gomez V, Galazi M, Weitsman G, Monypenny J, Al-Salemee F, Barber PR et al (2022) HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-21-0320
doi: 10.1158/1535-7163.MCT-21-0320
pubmed: 35086953
pmcid: 7612588
Giraud N, Buy X, Vuong NS, Gaston R, Cazeau AL, Catena V et al (2021) Single-center experience of focal thermo-ablative therapy after pelvic radiotherapy for in-field prostate cancer oligo-recurrence. Front Oncol 11:709779. https://doi.org/10.3389/fonc.2021.709779
doi: 10.3389/fonc.2021.709779
pubmed: 34381730
pmcid: 8350731
Abdo J, Cornell DL, Mittal SK, Agrawal DK (2018) Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers. Front Oncol 8:85. https://doi.org/10.3389/fonc.2018.00085
doi: 10.3389/fonc.2018.00085
pubmed: 29644213
pmcid: 5882833
Sheng MX, Wan LL, Liu CM, Liu CX, Chen SS (2017) Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: a retrospective analysis. Kaohsiung J Med Sci 33(12):609–615. https://doi.org/10.1016/j.kjms.2017.07.002
doi: 10.1016/j.kjms.2017.07.002
pubmed: 29132550
Sheng M, Wan L, Liu C, Liu C (2018) Is cryosurgery a feasible local therapy for bone metastatic prostate cancer? Singapore Med J 59(11):584–589. https://doi.org/10.11622/smedj.2018119
doi: 10.11622/smedj.2018119
pubmed: 30246213
pmcid: 6250764
Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, Neal TO et al (2020) A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis 23(1):184–193. https://doi.org/10.1038/s41391-019-0176-8
doi: 10.1038/s41391-019-0176-8
pubmed: 31611635
Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ et al (2021) A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol 80(3):280–292. https://doi.org/10.1016/j.eururo.2020.11.010
doi: 10.1016/j.eururo.2020.11.010
pubmed: 33309278
Fredman E, Traughber B, Kharouta M, Podder T, Lo S, Ponsky L et al (2021) Focal prostate stereotactic body radiation therapy with correlative pathological and radiographic-based treatment planning. Front Oncol 11:744130. https://doi.org/10.3389/fonc.2021.744130
doi: 10.3389/fonc.2021.744130
pubmed: 34604088
pmcid: 8480263
Tsoumakidou G, Mandralis K, Hocquelet A, Duran R, Denys A (2020) Salvage lymph-node percutaneous cryoablation: safety profile and oncologic outcomes. Cardiovasc Intervent Radiol 43(2):264–272. https://doi.org/10.1007/s00270-019-02341-3
doi: 10.1007/s00270-019-02341-3
pubmed: 31591690
Autrusseau PA, Cazzato RL, Koch G, Ramamurthy N, Auloge P, De Marini P et al (2021) Freezing nodal disease: local control following percutaneous image-guided cryoablation of locoregional and distant lymph node oligometastases: a 10-year, single-center experience. J Vasc Interv Radiol 32(10):1435–1444. https://doi.org/10.1016/j.jvir.2021.07.002
doi: 10.1016/j.jvir.2021.07.002
pubmed: 34271190
Cazzato RL, Garnon J, Ramamurthy N, Koch G, Tsoumakidou G, Caudrelier J et al (2016) Percutaneous image-guided cryoablation: current applications and results in the oncologic field. Med Oncol 33(12):140. https://doi.org/10.1007/s12032-016-0848-3
doi: 10.1007/s12032-016-0848-3
pubmed: 27837451
Cornelis FH, Durack JC, Morris MJ, Scher HI, Solomon SB (2017) Effective prostate-specific membrane antigen-based 18F-DCFPyL-guided cryoablation of a single positive site in a patient believed to be more metastatic on 11C-choline PET/CT. Clin Nucl Med 42(12):e516–e518. https://doi.org/10.1097/RLU.0000000000001846
doi: 10.1097/RLU.0000000000001846
pubmed: 29099733
pmcid: 5736003
Levy J, Hopkins T, Morris J, Tran ND, David E, Massari F et al (2020) Radiofrequency ablation for the palliative treatment of bone metastases: outcomes from the multicenter osteocool tumor ablation post-market study (OPuS One study) in 100 patients. J Vasc Interv Radiol 31(11):1745–1752. https://doi.org/10.1016/j.jvir.2020.07.014
doi: 10.1016/j.jvir.2020.07.014
pubmed: 33129427
Fares A, Shaaban MH, Reyad RM, Ragab AS, Sami MA (2018) Combined percutaneous radiofrequency ablation and cementoplasty for the treatment of extraspinal painful bone metastases: a prospective study. J Egypt Natl Canc Inst 30(3):117–122. https://doi.org/10.1016/j.jnci.2018.05.002
doi: 10.1016/j.jnci.2018.05.002
pubmed: 29958780
Mehta TI, Heiberger C, Kazi S, Brown M, Weissman S, Hong K et al (2020) Effectiveness of radiofrequency ablation in the treatment of painful osseous metastases: a correlation meta-analysis with machine learning cluster identification. J Vasc Interv Radiol 31(11):1753–1762. https://doi.org/10.1016/j.jvir.2020.08.002
doi: 10.1016/j.jvir.2020.08.002
pubmed: 33012648
Erie AJ, Morris JM, Welch BT, Kurup AN, Weisbrod AJ, Atwell TD et al (2017) Retrospective review of percutaneous image-guided ablation of oligometastatic prostate cancer: a single-institution experience. J Vasc Interv Radiol 28(7):987–992. https://doi.org/10.1016/j.jvir.2017.03.012
doi: 10.1016/j.jvir.2017.03.012
pubmed: 28434661
Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K et al (2016) Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. Eur Urol 69(1):9–12. https://doi.org/10.1016/j.eururo.2015.07.004
doi: 10.1016/j.eururo.2015.07.004
pubmed: 26189689
Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897. https://doi.org/10.1016/j.ijrobp.2010.11.031
doi: 10.1016/j.ijrobp.2010.11.031
pubmed: 21277113
Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T et al (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(5):479–505. https://doi.org/10.6004/jnccn.2019.0023
doi: 10.6004/jnccn.2019.0023
pubmed: 31085757
Rogowski P, Roach M 3rd, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R et al (2021) Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol 16(1):50. https://doi.org/10.1186/s13014-021-01776-8
doi: 10.1186/s13014-021-01776-8
pubmed: 33750437
pmcid: 7941976
Yan M, Moideen N, Bratti VF, Moraes FY (2020) Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence. Br J Radiol 93(1116):20200496. https://doi.org/10.1259/bjr.20200496
doi: 10.1259/bjr.20200496
pubmed: 32822547
pmcid: 7716008
Marvaso G, Volpe S, Pepa M, Augugliaro M, Corrao G, Biffi A et al (2021) Oligorecurrent prostate cancer and stereotactic body radiotherapy: where are we now? A systematic review and meta-analysis of prospective studies. Eur Urol Open Sci 27:19–28. https://doi.org/10.1016/j.euros.2021.02.008
doi: 10.1016/j.euros.2021.02.008
pubmed: 34337513
pmcid: 8317806
Viani GA, Arruda CV, Hamamura AC, Faustino AC, Freitas Bendo Danelichen A, Guimaraes FS (2020) Stereotactic body radiotherapy for oligometastatic prostate cancer recurrence: a meta-analysis. Am J Clin Oncol 43(2):73–81. https://doi.org/10.1097/COC.0000000000000635
doi: 10.1097/COC.0000000000000635
pubmed: 31809327
Olson R, Mathews L, Liu M, Schellenberg D, Mou B, Berrang T et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer 20(1):380. https://doi.org/10.1186/s12885-020-06876-4
doi: 10.1186/s12885-020-06876-4
pubmed: 32370765
pmcid: 7201684
Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA et al (2019) Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 19(1):816. https://doi.org/10.1186/s12885-019-5977-6
doi: 10.1186/s12885-019-5977-6
pubmed: 31426760
pmcid: 6699121
Connor MJ, Shah TT, Smigielska K, Day E, Sukumar J, Fiorentino F et al (2021) Additional treatments to the local tumour for metastatic prostate cancer-assessment of novel treatment algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open 11(2):e042953. https://doi.org/10.1136/bmjopen-2020-042953
doi: 10.1136/bmjopen-2020-042953
pubmed: 33632752
pmcid: 7908915